JW (Cayman) Therapeutics Co Ltd
HKEX:2126
P/OCF
Price to OCF
Price to Operating Cash Flow (P/OCF) ratio is a valuation multiple that measures the value of a company’s market capitalization relative to the operating cash flow it generates. Some analysts prefer P/OCF over P/E since earnings can be more easily manipulated than cash flows.
Market Cap | P/OCF | ||||
---|---|---|---|---|---|
CN |
JW (Cayman) Therapeutics Co Ltd
HKEX:2126
|
750.6m HKD | -1.7 | ||
US |
Abbvie Inc
NYSE:ABBV
|
283.3B USD | 12.4 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
164.8B USD | 20.4 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
107.9B USD | 30.5 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
105.3B USD | 22.2 | ||
AU |
CSL Ltd
ASX:CSL
|
135.1B AUD | 33 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
80.9B USD | 10.1 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
46.7B USD | -16.2 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | -79.9 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
32B USD | 19.4 | ||
KR |
Celltrion Inc
KRX:068270
|
40.3T KRW | 75.1 |
P/OCF Forward Multiples
Forward P/OCF multiple is a version of the P/OCF ratio that uses forecasted operating cash flow for the P/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.